Skip to content
Oncology Research Hub

Chicago, Illinois

Cancer clinical trials in Chicago, IL

337 cancer studies are recruiting participants at sites in Chicago as of November 16, 2026, according to ClinicalTrials.gov. Oncology Research Hub can help you understand your options and connect with a study team.

Call (888) 343-1186
  • No cost to ask
  • Taking part is voluntary
  • Studies are independently reviewed

Chicago at a glance

  • 337 studies are recruiting at a site in Chicago.
  • By phase: Early Phase 1 (5), Phase 1 (51), Phase 1/2 (45), Phase 2 (82), Phase 2/3 (7), Phase 3 (86), Phase 4 (4), No phase (28), Observational (29). Studies of devices and behavioral approaches have no phase.
  • By sponsor: university, hospital or other (153), industry (152), government (32).
  • By research area: Lung Cancer (95), Breast Cancer (87), Lymphoma (80), Prostate Cancer (39), Pancreatic Cancer (21), Melanoma (15).
  • Most recent update to one of these records: November 16, 2026.

Breast cancer studies recruiting in Chicago

Basic details from each study's public record (the 30 most recently updated of 337). Select a study to read the full record on ClinicalTrials.gov, including how to contact its team.

  1. BRE-13: Mediterranean Diet

    • No phase
    • Ages 18 to 80
    • Female participants
    Sponsor
    University of Illinois Chicago
    Study site
    University of Illinois at Chicago Campus
    Registry record
    NCT07869355 · updated
  2. S1501 Dual Observational and Randomized Cohort Study of Patients With Metastatic HER-2+ Breast Cancer at Risk of Cardiac Toxicity

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    SWOG Cancer Research Network
    Study site
    John H Stroger Jr Hospital of Cook County
    Registry record
    NCT03418961 · updated
  3. Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial

    • Phase 2
    • All ages
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study sites
    Advocate Illinois Masonic Medical Center · John H Stroger Jr Hospital of Cook County · Mount Sinai Hospital Medical Center
    Registry record
    NCT05564377 · updated

Source: ClinicalTrials.gov. Data processed . See every breast cancer study recruiting in Chicago, IL on ClinicalTrials.gov.

Lung cancer studies recruiting in Chicago

  1. Testing the Combination of an Anti-cancer Drug, Iadademstat, With Other Anti-cancer Drugs (Atezolizumab or Durvalumab) at Improving Outcomes for Small Cell Lung Cancer

    • Phase 1/2
    • Ages 18 and older
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study site
    University of Chicago Comprehensive Cancer Center
    Registry record
    NCT06287775 · updated
  2. A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202)

    • Phase 3
    • Ages 18 to 100
    • All sexes
    Sponsor
    Amgen
    Study site
    University of Illinois Chicago
    Registry record
    NCT05920356 · updated
  3. A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Non-Small Cell Lung Cancer

    • Phase 2
    • Ages 18 and older
    • All sexes
    Sponsor
    Verastem, Inc.
    Study site
    University of Chicago
    Registry record
    NCT07659782 · updated
  4. Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study sites
    Advocate Illinois Masonic Medical Center · John H Stroger Jr Hospital of Cook County · University of Chicago Comprehensive Cancer Center
    Registry record
    NCT04267848 · updated
  5. Testing Lutetium Lu 177 Dotatate in Patients With Somatostatin Receptor Positive Advanced Bronchial Neuroendocrine Tumors

    • Phase 2
    • Ages 18 and older
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study site
    University of Chicago Comprehensive Cancer Center
    Registry record
    NCT04665739 · updated
  6. Testing Tumor Tissue and Blood to Help Select Personalized Treatments for Patients With Suspected Lung Cancers

    • Observational
    • All ages
    • All sexes
    Sponsor
    Lung Cancer Mutation Consortium
    Study site
    Northwestern University
    Registry record
    NCT04712877 · updated

Source: ClinicalTrials.gov. Data processed . See every lung cancer study recruiting in Chicago, IL on ClinicalTrials.gov.

Prostate cancer studies recruiting in Chicago

  1. Treating Prostate Cancer That Has Come Back After Surgery With Apalutamide and Targeted Radiation Based on PET Imaging

    • Phase 3
    • Ages 18 and older
    • Male participants
    Sponsor
    ECOG-ACRIN Cancer Research Group
    Study sites
    Northwestern University · Rush MD Anderson Cancer Center · University of Illinois
    Registry record
    NCT04423211 · updated
  2. Study of Opevesostat (MK-5684) Versus Alternative NHA in mCRPC (MK-5684-003)

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    Merck Sharp & Dohme LLC
    Study sites
    University of Chicago Medical Center ( Site 0045) · University of Illinois at Chicago ( Site 0105)
    Registry record
    NCT06136624 · updated
  3. Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors

    • Phase 2
    • Ages 18 and older
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study sites
    Rush MD Anderson Cancer Center · University of Chicago Comprehensive Cancer Center
    Registry record
    NCT03866382 · updated
  4. Testing the Safety and Effectiveness of Radiation-based Treatment (Lutetium Lu 177 Dotatate) for Metastatic Prostate Cancer That Has Neuroendocrine Cells

    • Phase 2
    • Ages 18 and older
    • Male participants
    Sponsor
    National Cancer Institute (NCI)
    Study site
    Northwestern University
    Registry record
    NCT05691465 · updated

Source: ClinicalTrials.gov. Data processed . See every prostate cancer study recruiting in Chicago, IL on ClinicalTrials.gov.

Melanoma studies recruiting in Chicago

  1. Comparing the Effectiveness of Less Invasive Procedures With the Current Standard of Care for the Treatment of Older Adults With Early-Stage Melanoma

    • Phase 3
    • Ages 75 and older
    • All sexes
    Sponsor
    ECOG-ACRIN Cancer Research Group
    Study sites
    Northwestern University · Swedish Covenant Hospital
    Registry record
    NCT07068074 · updated
  2. A Study of Pembrolizumab (MK-3475) in Pediatric Participants With an Advanced Solid Tumor or Lymphoma (MK-3475-051/KEYNOTE-051)

    • Phase 1/2
    • From 6 months, up to 17 years
    • All sexes
    Sponsor
    Merck Sharp & Dohme LLC
    Study site
    Call for Information (Investigational Site 0024)
    Registry record
    NCT02332668 · updated
  3. BiCaZO: A Study Combining Two Immunotherapies (Cabozantinib and Nivolumab) to Treat Patients With Advanced Melanoma or Squamous Cell Head and Neck Cancer, an immunoMATCH Pilot Study

    • Phase 2
    • Ages 18 and older
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study sites
    Northwestern University · University of Illinois
    Registry record
    NCT05136196 · updated

Source: ClinicalTrials.gov. Data processed . See every melanoma study recruiting in Chicago, IL on ClinicalTrials.gov.

Lymphoma studies recruiting in Chicago

  1. Daratumumab for Chemotherapy-Refractory Minimal Residual Disease in T Cell ALL

    • Phase 2
    • Ages 18 and older
    • All sexes
    Sponsor
    Eastern Cooperative Oncology Group
    Study site
    Northwestern
    Registry record
    NCT05289687 · updated
  2. A Study of NX-5948 in Adults With CLL/SLL Previously Treated With a Bruton's Tyrosine Kinase Inhibitor and a B-cell Lymphoma-2 Inhibitor (DAYBreak CLL-201)

    • Phase 2
    • Ages 18 and older
    • All sexes
    Sponsor
    Nurix Therapeutics, Inc.
    Study site
    The University of Chicago
    Registry record
    NCT07221500 · updated
  3. A Study of CD19 Targeted CAR T Cell Therapy in Pediatric Patients With Relapsed or Refractory B Cell Acute Lymphoblastic Leukemia (B ALL) and Aggressive Mature B-cell Non-Hodgkin Lymphoma (B NHL)

    • Phase 1
    • Ages 0 to 18
    • All sexes
    Sponsor
    Autolus Limited
    Study site
    Lurie Children's Hospital
    Registry record
    NCT06173518 · updated
  4. A Clinical Study of Zilovertamab Vedotin (MK-2140) Plus Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Polatuzumab Vedotin Plus R-CHP in People With Diffuse Large B-cell Lymphoma (DLBCL) (MK-2140-011/waveLINE-011)

    • Phase 2
    • Ages 18 and older
    • All sexes
    Sponsor
    Merck Sharp & Dohme LLC
    Study site
    University of Chicago Medical Center ( Site 0126)
    Registry record
    NCT06890884 · updated
  5. Study of AZD4512 Monotherapy or in Combination With Anticancer Agents in Participants With Acute Lymphoblastic Leukemia

    • Phase 1/2
    • Ages 12 and older
    • All sexes
    Sponsor
    AstraZeneca
    Registry record
    NCT07109219 · updated
  6. Inotuzumab Ozogamicin and Blinatumomab With or Without Ponatinib in Treating Patients With Newly Diagnosed, Recurrent, or Refractory CD22-Positive B-Lineage Acute Lymphoblastic Leukemia

    • Phase 2
    • Ages 18 and older
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study sites
    Northwestern University · University of Chicago Comprehensive Cancer Center · University of Illinois
    Registry record
    NCT03739814 · updated
  7. Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL), EVOLVE CLL/SLL Study

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study sites
    Northwestern University · University of Chicago Comprehensive Cancer Center
    Registry record
    NCT04269902 · updated
  8. A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL)

    • Phase 2
    • Ages 1 to 30
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study sites
    Lurie Children's Hospital-Chicago · University of Chicago Comprehensive Cancer Center · University of Illinois
    Registry record
    NCT04546399 · updated
  9. Testing the Combination of Nivolumab and ASTX727 for Relapsed or Refractory B-Cell Lymphoma

    • Phase 1
    • Ages 18 and older
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study site
    University of Chicago Comprehensive Cancer Center
    Registry record
    NCT05272384 · updated
  10. A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and Nivolumab

    • Phase 3
    • Ages 5 to 60
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study sites
    Advocate Illinois Masonic Medical Center · Lurie Children's Hospital-Chicago · Mount Sinai Hospital Medical Center
    Registry record
    NCT05675410 · updated

Source: ClinicalTrials.gov. Data processed . See every lymphoma study recruiting in Chicago, IL on ClinicalTrials.gov.

Pancreatic cancer studies recruiting in Chicago

  1. Belzutifan/MK-6482 for the Treatment of Advanced Pheochromocytoma/Paraganglioma (PPGL), Pancreatic Neuroendocrine Tumor (pNET), Von Hippel-Lindau (VHL) Disease-Associated Tumors, Advanced Gastrointestinal Stromal Tumor (wt GIST), or Solid Tumors With HIF-2α Related Genetic Alterations (MK-6482-015)

    • Phase 2
    • Ages 12 and older
    • All sexes
    Sponsor
    Merck Sharp & Dohme LLC
    Study site
    Northwestern University - Robert H. Lurie Comprehensive Cancer Center ( Site 0130)
    Registry record
    NCT04924075 · updated
  2. A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Pancreatic Cancer

    • Phase 2
    • Ages 18 and older
    • All sexes
    Sponsor
    Verastem, Inc.
    Study site
    University of Chicago
    Registry record
    NCT07644559 · updated
  3. APOLLO: A Randomized Phase II Double-Blind Study of Olaparib Versus Placebo Following Curative Intent Therapy in Patients With Resected Pancreatic Cancer and a Pathogenic BRCA1, BRCA2 or PALB2 Mutation

    • Phase 2
    • Ages 18 and older
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study sites
    University of Chicago Comprehensive Cancer Center · University of Illinois
    Registry record
    NCT04858334 · updated
  4. Testing the Safety and Tolerability of the Anti-cancer Drugs Trastuzumab Deruxtecan and Neratinib for Cancers With Changes in the HER2 Gene

    • Phase 1
    • Ages 18 and older
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study site
    Northwestern University
    Registry record
    NCT05372614 · updated

Source: ClinicalTrials.gov. Data processed . See every pancreatic cancer study recruiting in Chicago, IL on ClinicalTrials.gov.

Ask about studies near Chicago

Tell us what you are looking for and a coordinator will contact you to talk through your options. Asking does not commit you to anything.

How should we reach you?
Add a message or the best time to reach you (optional)

Please do not include detailed medical information.

Before you contact a study

About these listings

These listings come from ClinicalTrials.gov, the study registry run by the U.S. National Library of Medicine. The data were processed on November 16, 2026. We show part of each public record (its title, phase, sponsor, basic eligibility and sites in this area) exactly as registered, and we group studies by place. Nothing in a record is reworded.

Oncology Research Hub does not run these studies and is not affiliated with their sponsors. A listing is not a recommendation, and only a study's own team can tell you whether you may be eligible. Follow the link on any study to read its full record and contact that team directly, or ask us and a coordinator will help you understand your options. How we source and check what we publish.

Sources and further reading

Ask about a study

A coordinator will contact you. Asking does not commit you to anything.

Call (888) 343-1186

or send a short form

How should we reach you?

Call